Christine M. Leeper
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Christine M. Leeper has a total of 261 co-authors. Here are the top co-authors by number of shared publications:
- Philip C. Spinella
Trauma and Transfusion Medicine Research Center, Department of Surgery University of Pittsburgh Pittsburgh Pennsylvania USA
23 shared publications - Mark H. Yazer
Department of Clinical Immunology Odense University Hospital Odense Denmark
21 shared publications Barbara A. Gaines
17 shared publicationsDarrell J. Triulzi
Department of Pathology University of Pittsburgh Pittsburgh Pennsylvania USA
8 shared publications- Jason L. Sperry
Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
8 shared publications - Joshua B. Brown
Department of Surgery, University of Pittsburgh
8 shared publications
Latest Publications
- 1 September 2026
- Published by Taylor & Francis in Prehospital Emergency Care
- p. 1-12
RhD-Positive Transfusion in Females of Childbearing Potential in Hemorrhagic Shock: Risk, Reality, and Policy
Prehospital transfusion using Rhesus D antigen (RhD)-positive low-titer group O whole blood (LTOWB) or red blood cells is increasingly common when RhD-negative blood products are not available. However, concerns remain regarding D-alloimmunization in RhD-negative females of childbearing potential (FCPs), which could lead to future hemolytic disease of the fetus and newborn (HDFN). The magnitude of these risks, and their policy implications, have been the subject of recent investigation. To summarize the biological and epidemiological impacts and post-exposure management of RhD-positive transfusion in FCPs in hemorrhagic shock. This narrative review synthesizes the literature on the rate of D-alloimmunization, describes the results of modeling studies on the risk of HDFN following RhD-positive transfusion to FCPs, and examines epidemiologic studies estimating the HDFN risk at local, regional, and national levels. The D-alloimmunization risk mitigation strategies and current clinical guidelines are also reviewed. Several factors, including the low prevalence of RhD-negative individuals, the low rate of D-alloimmunization itself, potentially reduced pregnancy rates post-trauma, and advances in modern perinatal care decrease the overall risk of HDFN following the transfusion of RhD-positive blood products to FCPs in trauma. Some modeling studies estimated that fetal death due to anti-D-mediated HDFN would occur in fewer than 0.1% of FCPs exposed to RhD-positive blood products. Timely prehospital transfusion has demonstrated survival benefits for injured adults and children. National and regional epidemiological studies support the safety and utility of RhD-positive blood product use in emergency settings. Risk mitigation strategies include Rh immune globulin (RhIg) administration and structured post-exposure follow-up to detect alloimmunization and reduce potential future pregnancy harm. RhD-positive transfusion in FCPs during hemorrhagic shock when RhD-negative products are not available is supported by current evidence and ethical considerations. The risk of future HDFN is low and favorable perinatal outcomes can be achieved when the woman has access to modern prenatal health care. Risk may be further mitigated through post-exposure protocols. Prehospital transfusion policies should reflect this risk-benefit balance by enabling access to RhD-positive blood products for all trauma patients, including FCPs, if RhD-negative blood products are not available.
- 1 September 2026
- Published by Taylor & Francis in Prehospital Emergency Care
- p. 1-12
RhD-Positive Transfusion in Females of Childbearing Potential in Hemorrhagic Shock: Risk, Reality, and Policy
Prehospital transfusion using Rhesus D antigen (RhD)-positive low-titer group O whole blood (LTOWB) or red blood cells is increasingly common when RhD-negative blood products are not available. However, concerns remain regarding D-alloimmunization in RhD-negative females of childbearing potential (FCPs), which could lead to future hemolytic disease of the fetus and newborn (HDFN). The magnitude of these risks, and their policy implications, have been the subject of recent investigation. To summarize the biological and epidemiological impacts and post-exposure management of RhD-positive transfusion in FCPs in hemorrhagic shock. This narrative review synthesizes the literature on the rate of D-alloimmunization, describes the results of modeling studies on the risk of HDFN following RhD-positive transfusion to FCPs, and examines epidemiologic studies estimating the HDFN risk at local, regional, and national levels. The D-alloimmunization risk mitigation strategies and current clinical guidelines are also reviewed. Several factors, including the low prevalence of RhD-negative individuals, the low rate of D-alloimmunization itself, potentially reduced pregnancy rates post-trauma, and advances in modern perinatal care decrease the overall risk of HDFN following the transfusion of RhD-positive blood products to FCPs in trauma. Some modeling studies estimated that fetal death due to anti-D-mediated HDFN would occur in fewer than 0.1% of FCPs exposed to RhD-positive blood products. Timely prehospital transfusion has demonstrated survival benefits for injured adults and children. National and regional epidemiological studies support the safety and utility of RhD-positive blood product use in emergency settings. Risk mitigation strategies include Rh immune globulin (RhIg) administration and structured post-exposure follow-up to detect alloimmunization and reduce potential future pregnancy harm. RhD-positive transfusion in FCPs during hemorrhagic shock when RhD-negative products are not available is supported by current evidence and ethical considerations. The risk of future HDFN is low and favorable perinatal outcomes can be achieved when the woman has access to modern prenatal health care. Risk may be further mitigated through post-exposure protocols. Prehospital transfusion policies should reflect this risk-benefit balance by enabling access to RhD-positive blood products for all trauma patients, including FCPs, if RhD-negative blood products are not available.
- Open Access
- 26 March 2026
- Published by Elsevier in Annals of Emergency Medicine
- Vol. 88 (1) , 107-109
Exception From Informed Consent Enrollment in Three Hemorrhagic Shock Trials
- 26 March 2026
- Published by Elsevier in Annals of Emergency Medicine
- Vol. 88 (1) , 107-109
Open AccessException From Informed Consent Enrollment in Three Hemorrhagic Shock Trials
- 24 March 2026
- Published by Wolters Kluwer Health in Journal of Trauma and Acute Care Surgery
- Vol. 101 (3) , 415-422
Consensus-based criteria for actionable hemorrhage in pediatric trauma: A Delphi study
BACKGROUND: Blood transfusion and hemorrhage control procedures can be unreliable surrogates for bleeding requiring intervention in children. Some receive unnecessary blood transfusions or lack intraoperative findings for hemorrhage, while others die before an intervention occurs. Standardized criteria for adjudicating the presence of actionable hemorrhage are needed. We aimed to define expert consensus criteria for retrospectively identifying actionable hemorrhage within 6 hours of emergency department (ED) arrival. METHODS: Experts from six specialties involved in pediatric trauma care participated in a modified Delphi study. Panelists were prompted to consider “actionable hemorrhage” as “severe bleeding or injuries at risk of progression to class III or IV shock without prompt intervention.” In Round 1, panelists answered five free-response questions identifying criteria for actionable hemorrhage, including indicators for transfusion and hemorrhage control procedures, postmortem findings, and other relevant factors. Responses were consolidated and rated on a five-point strength-of-indication scale in subsequent rounds. Consensus was defined a priori as ≥70% agreement among panelists. Stability of consensus ( p >0.05) between rounds was assessed using the Wilcoxon Signed-Rank Test. RESULTS: Three Delphi rounds were required to achieve a stable consensus. Twenty-nine of 32 participating panelists participated in all three rounds. Thirteen statements achieved stable consensus as strong indicators of actionable hemorrhage. Criteria with the highest agreement included partial/total resection of intrathoracic/abdominal bleeding solid organs (96.4%), hemoglobinJ Trauma Acute Care Surg . 2026;00:00-00. Copyright © 2026 Wolters Kluwer Health, Inc. All rights reserved.) LEVEL OF EVIDENCE: Diagnostic Test/Criteria; Level III.
- 24 March 2026
- Published by Wolters Kluwer Health in Journal of Trauma and Acute Care Surgery
- Vol. 101 (3) , 415-422
Consensus-based criteria for actionable hemorrhage in pediatric trauma: A Delphi study
BACKGROUND: Blood transfusion and hemorrhage control procedures can be unreliable surrogates for bleeding requiring intervention in children. Some receive unnecessary blood transfusions or lack intraoperative findings for hemorrhage, while others die before an intervention occurs. Standardized criteria for adjudicating the presence of actionable hemorrhage are needed. We aimed to define expert consensus criteria for retrospectively identifying actionable hemorrhage within 6 hours of emergency department (ED) arrival. METHODS: Experts from six specialties involved in pediatric trauma care participated in a modified Delphi study. Panelists were prompted to consider “actionable hemorrhage” as “severe bleeding or injuries at risk of progression to class III or IV shock without prompt intervention.” In Round 1, panelists answered five free-response questions identifying criteria for actionable hemorrhage, including indicators for transfusion and hemorrhage control procedures, postmortem findings, and other relevant factors. Responses were consolidated and rated on a five-point strength-of-indication scale in subsequent rounds. Consensus was defined a priori as ≥70% agreement among panelists. Stability of consensus ( p >0.05) between rounds was assessed using the Wilcoxon Signed-Rank Test. RESULTS: Three Delphi rounds were required to achieve a stable consensus. Twenty-nine of 32 participating panelists participated in all three rounds. Thirteen statements achieved stable consensus as strong indicators of actionable hemorrhage. Criteria with the highest agreement included partial/total resection of intrathoracic/abdominal bleeding solid organs (96.4%), hemoglobinJ Trauma Acute Care Surg . 2026;00:00-00. Copyright © 2026 Wolters Kluwer Health, Inc. All rights reserved.) LEVEL OF EVIDENCE: Diagnostic Test/Criteria; Level III.
- 1 February 2026
- Published by Wolters Kluwer Health in Journal of Trauma and Acute Care Surgery
- Vol. 100 (2) , 221-226
Whole blood resuscitation is associated with decreased end-organ dysfunction in pediatric trauma patients
INTRODUCTION: Low Titer Group O Whole Blood (WB) has emerged as a safe and efficient therapeutic agent for hemostatic resuscitation in injured children. The relationship between type of blood product transfused and incidence of organ dysfunction is not well elucidated. We hypothesize that WB transfusion is associated with decreased organ dysfunction compared with component therapy (CT). METHODS: This is a retrospective observational study of injured children ages 0 year to 17 years utilizing the TQIP database (2020–2022). Inclusion criteria were receipt of any blood product within 4 hours of ED arrival and survival to 72 hours. Subjects were categorized by receipt of WB. Primary outcome was organ dysfunction, defined as presence of any of the following: mechanical ventilation greater than 6 days, sepsis, acute respiratory distress syndrome, pneumonia, acute kidney injury, urinary tract infection, or myocardial infarction. Data were analyzed using logistic regression, adjusting for age, sex, trauma mechanism, Injury Severity Score, head abbreviated injury score, Glasgow Coma Scale, shock (SIPA score), interfacility transfer, weight-adjusted volume of each blood product (mL/kg) and site. RESULTS: Of 6237 subjects analyzed, 907 (14.5%) received WB and 2421 (38.8%) had evidence of organ dysfunction, with respiratory failure being most common (1689 [27%]). In the analysis cohort, the median (IQR) age was 15 years (10–17), 42.7% penetrating mechanism, median (IQR) injury severity score 24 (14–43), median (IQR) total transfusion volume 16.4 mL/kg (8.2–35), and median (IQR) WB transfusion volume 12 mL/kg (7–20). In the adjusted model, WB transfusion was associated with decreased odds of organ dysfunction (odds ratio, 0.78; 95% confidence interval, 0.61–0.98; p = 0.04). Sensitivity analysis including subjects who died within 72-hours did not show a significant difference, suggesting minimal influence of survival bias. CONCLUSION: Early WB resuscitation was independently associated with reduced organ dysfunction in injured children. Further large, prospective, and mechanistic studies are needed. LEVEL OF EVIDENCE: Therapeutic/Care Management; Level III.
- 1 February 2026
- Published by Wolters Kluwer Health in Journal of Trauma and Acute Care Surgery
- Vol. 100 (2) , 221-226
Whole blood resuscitation is associated with decreased end-organ dysfunction in pediatric trauma patients
INTRODUCTION: Low Titer Group O Whole Blood (WB) has emerged as a safe and efficient therapeutic agent for hemostatic resuscitation in injured children. The relationship between type of blood product transfused and incidence of organ dysfunction is not well elucidated. We hypothesize that WB transfusion is associated with decreased organ dysfunction compared with component therapy (CT). METHODS: This is a retrospective observational study of injured children ages 0 year to 17 years utilizing the TQIP database (2020–2022). Inclusion criteria were receipt of any blood product within 4 hours of ED arrival and survival to 72 hours. Subjects were categorized by receipt of WB. Primary outcome was organ dysfunction, defined as presence of any of the following: mechanical ventilation greater than 6 days, sepsis, acute respiratory distress syndrome, pneumonia, acute kidney injury, urinary tract infection, or myocardial infarction. Data were analyzed using logistic regression, adjusting for age, sex, trauma mechanism, Injury Severity Score, head abbreviated injury score, Glasgow Coma Scale, shock (SIPA score), interfacility transfer, weight-adjusted volume of each blood product (mL/kg) and site. RESULTS: Of 6237 subjects analyzed, 907 (14.5%) received WB and 2421 (38.8%) had evidence of organ dysfunction, with respiratory failure being most common (1689 [27%]). In the analysis cohort, the median (IQR) age was 15 years (10–17), 42.7% penetrating mechanism, median (IQR) injury severity score 24 (14–43), median (IQR) total transfusion volume 16.4 mL/kg (8.2–35), and median (IQR) WB transfusion volume 12 mL/kg (7–20). In the adjusted model, WB transfusion was associated with decreased odds of organ dysfunction (odds ratio, 0.78; 95% confidence interval, 0.61–0.98; p = 0.04). Sensitivity analysis including subjects who died within 72-hours did not show a significant difference, suggesting minimal influence of survival bias. CONCLUSION: Early WB resuscitation was independently associated with reduced organ dysfunction in injured children. Further large, prospective, and mechanistic studies are needed. LEVEL OF EVIDENCE: Therapeutic/Care Management; Level III.
- Open Access
- 10 January 2026
- Published by Wiley in Transfusion
- Vol. 66 (S1) , S82-S86
Survey of quality control testing practices on low titer group O whole blood in the United States
Background: Use of low titer group O whole blood (LTOWB) continues to increase in the United States (US). This survey sampled the quality control (QC) practices among the largest blood collectors in the US. Methods: A survey on LTOWB collection, QC testing, and distribution was developed and electronically distributed to the chief medical officers of 16 large blood collectors in the US. Only complete survey responses were included. Results: The response rate was 10/16 (63%) representing approximately 80% of the US blood supply as estimated by the respondents. All of the respondents collected LTOWB from males and 7/10 (70%) also collected from never pregnant females. Eight out of nine (89%) centers that repeat donor anti‐A and ‐B titer testing do so on every donation, with 1/9 (11%) respondent testing previously low titer donors annually. The most common antibody titer threshold that defined low titer was <200 (6/10, 60%). The most common LTOWB collection method was with a platelet‐sparing filter in CPD 5/10 (50%). 7/10 (70%) respondents performed QC testing on LTOWB units; all of these respondents collected leukoreduced LTOWB and performed residual leukocyte count testing following leukoreduction. 6/7 (86%) performed residual red blood cell (RBC) recovery counts in the laboratory, 4/7 (57%) measured the unit's weight/volume, while 1/7 (14%) center measured the time taken for leukoreduction. The most often frequency of QC testing was monthly. Conclusion: Current practice at US blood suppliers for QC testing on LTOWB units was limited primarily to testing associated with leukoreduction and RBC counting.
- 10 January 2026
- Published by Wiley in Transfusion
- Vol. 66 (S1) , S82-S86
Open AccessSurvey of quality control testing practices on low titer group O whole blood in the United States
Background: Use of low titer group O whole blood (LTOWB) continues to increase in the United States (US). This survey sampled the quality control (QC) practices among the largest blood collectors in the US. Methods: A survey on LTOWB collection, QC testing, and distribution was developed and electronically distributed to the chief medical officers of 16 large blood collectors in the US. Only complete survey responses were included. Results: The response rate was 10/16 (63%) representing approximately 80% of the US blood supply as estimated by the respondents. All of the respondents collected LTOWB from males and 7/10 (70%) also collected from never pregnant females. Eight out of nine (89%) centers that repeat donor anti‐A and ‐B titer testing do so on every donation, with 1/9 (11%) respondent testing previously low titer donors annually. The most common antibody titer threshold that defined low titer was <200 (6/10, 60%). The most common LTOWB collection method was with a platelet‐sparing filter in CPD 5/10 (50%). 7/10 (70%) respondents performed QC testing on LTOWB units; all of these respondents collected leukoreduced LTOWB and performed residual leukocyte count testing following leukoreduction. 6/7 (86%) performed residual red blood cell (RBC) recovery counts in the laboratory, 4/7 (57%) measured the unit's weight/volume, while 1/7 (14%) center measured the time taken for leukoreduction. The most often frequency of QC testing was monthly. Conclusion: Current practice at US blood suppliers for QC testing on LTOWB units was limited primarily to testing associated with leukoreduction and RBC counting.
- Open Access
- 26 August 2025
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 9 (6)
Beyond the count: platelet dysfunction profile in pediatric trauma patients
- 26 August 2025
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 9 (6)
Open AccessBeyond the count: platelet dysfunction profile in pediatric trauma patients
- Open Access
- 5 August 2025
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 60 (10) , 162500
Impact of Early Plasma Resuscitation in Pediatric Severe Traumatic Brain Injury
- 5 August 2025
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 60 (10) , 162500
Open AccessImpact of Early Plasma Resuscitation in Pediatric Severe Traumatic Brain Injury
- 30 July 2025
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 60 (10) , 162494
Pediatric Tourniquet Use: Safe and effective
- 30 July 2025
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 60 (10) , 162494
Pediatric Tourniquet Use: Safe and effective
- 13 June 2025
- Published by Wolters Kluwer Health in Journal of Trauma and Acute Care Surgery
- Vol. 99 (3) , 382-386
Waiting to initiate venous thromboembolism prophylaxis increases the incidence of venous thromboembolism in pediatric patients with traumatic bleeding
BACKGROUND: We aim to evaluate the relationship between timing of venous thromboembolism (VTE) prophylaxis initiation and incidence of VTE in a high-risk cohort of injured children. METHODS: This is a retrospective analysis of the Acute Care Surgery Trauma Quality Improvement Program database (2020–2022). Injured children (younger than 18 years) who received blood products or underwent hemorrhage control surgery within 4 hours of arrival were included. The primary outcome was VTE (deep venous thrombosis or pulmonary embolism). Multivariable analysis assessed the relationship between timing of VTE prophylaxis and VTE, adjusting for prophylaxis agent, type of surgery, head injury severity, interfacility transfer, total 4-hour blood product administration, injury mechanism, Injury Severity Score, age, sex, and trauma center level, clustered by facility. Missing data were imputed. Subgroup analyses include age younger than 15 years. RESULTS: Of 4,575 children included, 3,902 underwent hemorrhage control surgery, and 4,141 received blood product transfusion. In total, 185 (4%) developed VTE (n = 154 deep venous thrombosis and/or n = 45 pulmonary embolism). The VTE cohort was older (16 [15–17] vs. 16 [13–17] years), had higher Injury Severity Score (27 [19–36] vs. 25 [14–35]), and was more likely to be in shock on arrival based on shock index, pediatric age-adjusted score (75% vs. 64%). The rate of prophylaxis was 51%, with common agents being low-molecular-weight heparin (38%) and unfractionated heparin (11%). The median (interquartile range) time to initiation of prophylaxis was 2 (2–4) days. In the multivariable analysis, every 1-day delay to initiation of VTE prophylaxis was associated with 6% increase in odds of VTE (odds ratio [95% confidence interval], 1.06 [1.03–1.10]; p < 0.001). In a subset of children younger than 15 years with VTE incidence of 3%, this relationship persisted (every 1-day delay = 4% increase in odds of VTE; odds ratio, 1.04 [1.01–1.07]; p = 0.04). CONCLUSION: Earlier VTE prophylaxis initiation was associated with decreased odds of VTE development in this high-risk pediatric cohort, highlighting opportunities to optimize VTE prevention. Future multicenter studies regarding safety and therapeutic agent of choice are required. LEVEL OF EVIDENCE: Therapeutic/Care Management; Level III.
- 13 June 2025
- Published by Wolters Kluwer Health in Journal of Trauma and Acute Care Surgery
- Vol. 99 (3) , 382-386
Waiting to initiate venous thromboembolism prophylaxis increases the incidence of venous thromboembolism in pediatric patients with traumatic bleeding
BACKGROUND: We aim to evaluate the relationship between timing of venous thromboembolism (VTE) prophylaxis initiation and incidence of VTE in a high-risk cohort of injured children. METHODS: This is a retrospective analysis of the Acute Care Surgery Trauma Quality Improvement Program database (2020–2022). Injured children (younger than 18 years) who received blood products or underwent hemorrhage control surgery within 4 hours of arrival were included. The primary outcome was VTE (deep venous thrombosis or pulmonary embolism). Multivariable analysis assessed the relationship between timing of VTE prophylaxis and VTE, adjusting for prophylaxis agent, type of surgery, head injury severity, interfacility transfer, total 4-hour blood product administration, injury mechanism, Injury Severity Score, age, sex, and trauma center level, clustered by facility. Missing data were imputed. Subgroup analyses include age younger than 15 years. RESULTS: Of 4,575 children included, 3,902 underwent hemorrhage control surgery, and 4,141 received blood product transfusion. In total, 185 (4%) developed VTE (n = 154 deep venous thrombosis and/or n = 45 pulmonary embolism). The VTE cohort was older (16 [15–17] vs. 16 [13–17] years), had higher Injury Severity Score (27 [19–36] vs. 25 [14–35]), and was more likely to be in shock on arrival based on shock index, pediatric age-adjusted score (75% vs. 64%). The rate of prophylaxis was 51%, with common agents being low-molecular-weight heparin (38%) and unfractionated heparin (11%). The median (interquartile range) time to initiation of prophylaxis was 2 (2–4) days. In the multivariable analysis, every 1-day delay to initiation of VTE prophylaxis was associated with 6% increase in odds of VTE (odds ratio [95% confidence interval], 1.06 [1.03–1.10]; p < 0.001). In a subset of children younger than 15 years with VTE incidence of 3%, this relationship persisted (every 1-day delay = 4% increase in odds of VTE; odds ratio, 1.04 [1.01–1.07]; p = 0.04). CONCLUSION: Earlier VTE prophylaxis initiation was associated with decreased odds of VTE development in this high-risk pediatric cohort, highlighting opportunities to optimize VTE prevention. Future multicenter studies regarding safety and therapeutic agent of choice are required. LEVEL OF EVIDENCE: Therapeutic/Care Management; Level III.
- Open Access
- 28 April 2025
- Published by Wiley in Transfusion
- Vol. 65 (S1) , S173-S180
Expanding beyond trauma: Characterizing low titer group O whole blood (LTOWB) use in children requiring massive transfusion protocol activation
Introduction: Data regarding low titer group O whole blood (LTOWB) use for hemostatic resuscitation is largely derived from trauma cohorts; studies regarding its use in uninjured pediatric patients are lacking.Methods: The blood bank database from a single academic pediatric hospital with a massive transfusion protocol (MTP) allowing the use of LTOWB for any severe bleeding etiology was queried between 2016 and 2023. Pediatric (age n = 7) and non‐group O (n = 9) LTOWB recipients at any time point (p = .07–.99).Conclusions: LTOWB use was feasible in the resuscitation of children with various bleeding etiologies requiring massive transfusion. Larger prospective investigations are needed to inform guidelines for optimal use in this cohort.Level of Evidence: Retrospective Observational Study.
- 28 April 2025
- Published by Wiley in Transfusion
- Vol. 65 (S1) , S173-S180
Open AccessExpanding beyond trauma: Characterizing low titer group O whole blood (LTOWB) use in children requiring massive transfusion protocol activation
Introduction: Data regarding low titer group O whole blood (LTOWB) use for hemostatic resuscitation is largely derived from trauma cohorts; studies regarding its use in uninjured pediatric patients are lacking.Methods: The blood bank database from a single academic pediatric hospital with a massive transfusion protocol (MTP) allowing the use of LTOWB for any severe bleeding etiology was queried between 2016 and 2023. Pediatric (age n = 7) and non‐group O (n = 9) LTOWB recipients at any time point (p = .07–.99).Conclusions: LTOWB use was feasible in the resuscitation of children with various bleeding etiologies requiring massive transfusion. Larger prospective investigations are needed to inform guidelines for optimal use in this cohort.Level of Evidence: Retrospective Observational Study.